Amalgamated Bank Sells 1,136 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Amalgamated Bank lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXELGet Rating) by 0.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 232,559 shares of the biotechnology company’s stock after selling 1,136 shares during the period. Amalgamated Bank’s holdings in Exelixis were worth $5,272,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in EXEL. Point72 Asset Management L.P. grew its position in Exelixis by 98.0% during the fourth quarter. Point72 Asset Management L.P. now owns 4,222,146 shares of the biotechnology company’s stock valued at $77,181,000 after buying an additional 2,089,846 shares during the period. Farallon Capital Management LLC grew its position in Exelixis by 18.7% during the first quarter. Farallon Capital Management LLC now owns 10,520,061 shares of the biotechnology company’s stock valued at $238,490,000 after buying an additional 1,660,904 shares during the period. American Century Companies Inc. grew its position in Exelixis by 3,235.4% during the first quarter. American Century Companies Inc. now owns 1,706,245 shares of the biotechnology company’s stock valued at $38,681,000 after buying an additional 1,655,090 shares during the period. D. E. Shaw & Co. Inc. grew its position in Exelixis by 140.8% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,790,979 shares of the biotechnology company’s stock valued at $32,739,000 after buying an additional 1,047,159 shares during the period. Finally, First Trust Advisors LP grew its position in Exelixis by 30.6% during the first quarter. First Trust Advisors LP now owns 3,562,353 shares of the biotechnology company’s stock valued at $80,759,000 after buying an additional 835,621 shares during the period. Institutional investors own 85.25% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on EXEL. Morgan Stanley increased their price target on shares of Exelixis from $22.00 to $23.00 and gave the company an “equal weight” rating in a research report on Friday, July 15th. BMO Capital Markets started coverage on shares of Exelixis in a report on Thursday, June 23rd. They set an “outperform” rating and a $28.00 price objective on the stock. TheStreet downgraded shares of Exelixis from a “b-” rating to a “c+” rating in a report on Tuesday, September 13th. Cowen upped their price objective on shares of Exelixis to $26.00 in a report on Monday, August 15th. Finally, Piper Sandler upped their price objective on shares of Exelixis from $30.00 to $32.00 and gave the company an “overweight” rating in a report on Tuesday, July 26th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.56.

Exelixis Trading Down 1.3 %

Shares of Exelixis stock opened at $16.92 on Tuesday. Exelixis, Inc. has a 12-month low of $15.50 and a 12-month high of $23.40. The company has a market cap of $5.45 billion, a price-to-earnings ratio of 20.14, a PEG ratio of 0.54 and a beta of 0.65. The company’s 50-day moving average price is $19.58 and its 200-day moving average price is $20.38.

Insider Transactions at Exelixis

In other news, EVP Patrick J. Haley sold 40,000 shares of the stock in a transaction dated Monday, September 12th. The shares were sold at an average price of $17.94, for a total value of $717,600.00. Following the sale, the executive vice president now directly owns 261,591 shares of the company’s stock, valued at $4,692,942.54. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.90% of the company’s stock.

About Exelixis

(Get Rating)

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Stories

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXELGet Rating).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.